MISSOULA, Montana, January 8, 2024
NEW YORK, New York, January 8, 2024
Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy. The combination of these two approaches is expected to result in the rapid and long-term relief of allergic symptoms resulting from peanut exposure and would be a game changer for patients suffering with this potentially life-threatening allergy.
“The combination provides an opportunity to significantly advance the prevention of allergic symptoms related to exposure to peanut allergen in susceptible individuals. The combination of technologies provided by each company can completely change the treatment paradigm associated with serious food related allergic reactions,” said Alan Joslyn, Ph.D., Inimmune’s CEO. “We look forward to advancing the combined technologies into the clinic in the near future.”
The two companies plan to work together to evaluate the potential for combining the two clinical
stage immunotherapies.
Oral mucosal immunotherapy utilizes complex patented biochemical processes to stabilize and deliver allergenic proteins in a fully functional toothpaste. Through the act of tooth brushing, the allergenic proteins can be delivered to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization.
“This collaborative opportunity between Intrommune and Inimmune represents a significant step forward in the fight to reduce the physical and psychological burden that food allergies have on millions of individuals living with food allergy,” said Michael Nelson, Intrommune’s founder and CEO. “By combining our disease-modifying, patient-friendly treatment platform with Inimmune’s proprietary rapid desensitization technology, we look to create a future free from the fear of food allergies.”
About Inimmune Corporation
Inimmune Corp. (Missoula, MT) is a privately held clinical stage biotechnology company focused on the
discovery and development of Disease modifying immunotherapies. Inimmune designs novel
compounds to target relevant pathways of the innate immune system to create safe and effective
treatments for allergy, infectious disease, autoimmunity and cancer. Their laboratories and offices are
housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.
For more information on Inimmune’s research and development of novel immunotherapies, vaccine
adjuvants, and delivery systems, please visit www.inimmune.com.
